Interpace Biosciences Announces Divestiture of New Haven CLIA lab to DiamiR
March 17, 2021 07:30 ET | Source: Interpace Biosciences, Inc. Interpace Biosciences, Inc.
Part of Company’s Site Consolidation and Cost Savings Measures
Parsippany, NJ, March 17, 2021 (GLOBE NEWSWIRE) Interpace Biosciences, Inc. (OTC: IDXG) announced today that it has entered into a definitive agreement to sell its New Haven CT CLIA certified, CAP accredited laboratory to DiamiR Biosciences, Corp. (DiamiR). This sale is in line with previously announced restructuring and cost reduction initiatives announced by Interpace. Under this agreement, DiamiR will provide overflow lab testing in support of the Company’s molecular thyroid testing products at its main laboratory in Pittsburgh, PA. DiamiR will also support specific Interpace assay development and validation services on behalf of the Company for the next three quarters. Subject to specific terms and conditions of